Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated
Interferon-alpha (IFN-alpha) treatment in both oncological and hepatological settings is associated with depression. If IFN-alpha treatment induces depression in high numbers, it could serve as a model for studying the pathophysiology of depression, in general. The authors therefore studied 43 oncology patients treated with standard or pegylated IFN-alpha with baseline psychiatric assessment and at regular time-points in the first 6 months of treatment. Apart from a severe depression because of brain metastases, authors observed only two clinically relevant depressive states. Contrary to findings in most of the literature, most depressive episodes in this study were self-limiting and short-lasting and were associated with either episodes of flu-like symptoms common at the start of the treatment or with concurrent psychosocial events. In the group as a whole, scores on both observer-based and self-report rating scales did not show clinically relevant changes. The results of this study indicate that IFN-alpha treatment is not suitable as a study model for depression in general.
|Persistent URL||dx.doi.org/10.1176/appi.psy.49.1.56, hdl.handle.net/1765/15993|
Bannink, M., Kruit, W.H.J., van Gool, A.R., Sleijfer, S., van der Holt, B., Eggermont, A.M.M., … Hengeveld, M.W.. (2008). Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated. Psychosomatics: the journal of consultation and liaison psychiatry, 49(1), 56–63. doi:10.1176/appi.psy.49.1.56